• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.85% Nasdaq Up1.56%

    Array BioPharma Inc. (ARRY)

    5.07 Down 0.04(0.78%) Oct 5, 4:00PM EDT
    |After Hours : 5.07 Up 0.00 (0.02%) Oct 5, 4:43PM EDT
    ProfileGet Profile for:
    Array BioPharma Inc.
    3200 Walnut Street
    Boulder, CO 80301
    United States - Map
    Phone: 303-381-6600
    Website: http://www.arraybiopharma.com

    Index Membership:N/A
    Full Time Employees:156

    Business Summary 

    Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s drugs in Phase III clinical trials include Binimetinib and Encorafenib for the treatment of cancer. Its drug candidates in Phase II clinical trials include Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASC08/Danoprevir, a protease inhibitor for Hepatitis C virus; ASLAN001/ARRY-543, a pan-HER inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; and LY2606368, a chk-1 inhibitor for cancer. The company’s Phase Ib drug candidate comprises GDC-0575, a chk-1 inhibitor for cancer; and ONT-380/ARRY-380, a HER2 inhibitor for breast cancer, as well as Phase I drug candidate includes GDC-0994, an ERK inhibitor for cancer and LOXO-101, a PanTrk inhibitor for cancer. Array BioPharma Inc. has collaboration agreements with Biogen Idec MA Inc.; Array and Celgene Corporation and Celgene Alpine Investment Co., LLC; Genentech, Inc.; Loxo Oncology, Inc.; Novartis International Pharmaceutical Ltd.; and Oncothyreon Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Array BioPharma Inc.

    Corporate Governance 
    Array BioPharma Inc.’s ISS Governance QuickScore as of Oct 1, 2015 is 8. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 8; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Ron Squarer BSc (Biochemistry), MBA, 48
    Chief Exec. Officer and Director
    Mr. Andrew Robbins , 39
    Chief Operating Officer
    Mr. John R. Moore , 51
    VP, Gen. Counsel and Sec.
    Dr. Victor Sandor M.D., C.M, 49
    Chief Medical Officer
    Ms. Mary Patricia Henahan ,
    Chief Financial Officer
    Dr. Nicholas A. Saccomano Ph.D., 56
    Chief Scientific Officer
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders